During the past decade, Nagoya Daini Red Cross Hospital conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 20 clinical trials were completed, i.e. on average, 71.4% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 11 clinical trials were completed. i.e. 91.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Nagoya Daini Red Cross Hospital" #1 sponsor was "Pfizer" with 7 trials, followed by "Boehringer Ingelheim" with 6 trials sponsored, "Celgene" with 3 trials sponsored, "Incyte Corporation" with 3 trials sponsored and "Abbott Medical Devices" with 3 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nagoya Daini Red Cross Hospital" #1 collaborator was "UCB Pharma" with 4 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Japan Lung Cancer Society" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator and "ICON Clinical Research" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Nagoya Daini Red Cross Hospital" are "Heart Failure" (4 trials), "Atrial Fibrillation" (3 trials), "Coronary Artery Disease" (3 trials), "Angina Pectoris" (2 trials) and "Coronary Artery Occlusion" (2 trials). Many other conditions were trialed in "Nagoya Daini Red Cross Hospital" in a lesser frequency.

Most popular intervention types in "Nagoya Daini Red Cross Hospital" are "Drug" (33 trials), "Device" (5 trials), "Biological" (3 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "parsaclisib" (4 trials), "placebo" (3 trials), "Dabigatran Etexilate 150mg" (2 trials) and "Empagliflozin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Nagoya Daini Red Cross Hospital" are 43 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Nagoya Daini Red Cross Hospital". undefined are not yet recruiting, 8 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in Nagoya Daini Red Cross Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Nagoya Daini Red Cross Hospital, 7 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".